SCHEMBL6727015

SCHEMBL6727015

Cc1ccccc1NC(=O)C(NC(=O)O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
HPGD P15428 4/20 0.51
POLB P06746 3/20 0.51
ALDH1A1 P00352 1/20 0.51
ITGB3 P05106 2/20 0.50
ITGAV P06756 2/20 0.50
ITGB1 P05556 1/20 0.50
ITGA5 P08648 1/20 0.50
PGR P06401 1/20 0.49
SCN1A P35498 1/20 0.49
SCN2A Q99250 1/20 0.49
SCN3A Q9NY46 1/20 0.49
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726608 0.89 MAPT (0.51) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL28920385 0.89 POLB (0.56) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6715799 0.87 CYP1A2 (0.53) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6718465 0.85 MEN1 (0.55) HTTPOLBALDH1A1MEN1THRB
SCHEMBL6824801 0.85 BRD4 (0.60) HTTRAB9AALDH1A1MEN1THRB
SCHEMBL6715541 0.84 ULK1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6722718 0.84 MEN1 (0.64) CYP3A4CYP2C19HTTPOLBALDH1A1
SCHEMBL8337352 0.83 CTSS (0.60) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL8348009 0.83 CTSS (0.60) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL6827440 0.83 KMT2A (0.55) NPC1RAB9APOLBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 CYP1A2 348/4885CYP3A4 403/4885CYP2D6 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.